Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4<sup>+</sup> T cells through regulating type 2 conventional dendritic cells
Jing Luo, S.S. Pang, Zhenzhen Hui, Hua Zhao, Shilei Xu, Wenwen Yu, Lili Yang, Qian Sun, Xishan Hao, Wei Feng, Jian Wang, Xiubao Ren
Abstract
T cells through regulating cDC2. It also revealed an intrinsic barrier to ADU-S100 monotherapy, besides providing a combinatorial strategy for overcoming immunosuppression in tumors.
Topics & Concepts
Tumor microenvironmentDendritic cellCancer researchImmunotherapyTumor antigenCD8Cancer immunotherapyT cellImmunologyImmune systemMedicineBiologyinterferon and immune responsesGalectins and Cancer BiologyImmunotherapy and Immune Responses